NCT04080206View on ClinicalTrials.gov

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 7, 2020

Primary Completion Date

January 20, 2021

Study Completion Date

January 20, 2021

Conditions

Plaque Psoriasis

Interventions

DRUG

188-0551 Spray

Applied topically twice daily for two weeks

DRUG

RLD

Applied topically twice daily for two weeks

Trial Locations (8)

33147

TI Site #11, Miami

85258

TI Site #13, Scottsdale

91320

TI Site #12, Thousand Oaks

Unknown

TI Site #31, Batumi

TI Site #32, Tbilisi

TI Site #23, Lviv

TI Site #22, Rivne

TI Site #21, Zaporizhzhya

All Listed Sponsors

lead

Therapeutics, Inc.

INDUSTRY

NCT04080206 - A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis | Biotech Hunter | Biotech Hunter